

## TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

**Name of the Issue:**

Laxmi Dental Limited

- 
1. **Type of Issue (IPO/FPO)** IPO
  2. **Issue Size (Rs. Cr)** INR 698.06 Cr
  3. **Grade of issue along with name of the rating agency**

**Name**

**Grade**

NA

NA
  4. **Subscription Level (Number of times)** 114.67 times (excluding the Anchor Investor Portion) as per the bid books of NSE and BSE after removing multiple and duplicate bids.

Source: Minutes of the Meeting held for the finalization of the Basis of Allotment dated January 16, 2025

### 5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	44.67 %
(ii) at the end of the 1st Quarter immediately after the listing of the issue@	47.10%
(iii) at the end of 1st FY (March 31, 2025)@	47.10%
(iv) at the end of 2nd FY (March 31, 2026)^	NA
(v) at the end of 3rd FY (March 31, 2027)^	NA

(\*) As per the shareholding pattern as on the date of listing.

(^) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed.

@ Shareholding Pattern as on March 31, 2025

### 6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2025)@	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from operations	236.56	N.A.	N.A.
Net Profit for the period	25.37	N.A.	N.A.
Paid-up equity share capital	10.99	N.A.	N.A.
Reserves excluding revaluation reserves	197.54	N.A.	N.A.

\* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

@ Source : Audited Financial Results as on March 31, 2025

## 7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the BSE Limited and the National Stock Exchange of India Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.

\* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

## 8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed/ Resigned
(i) at the end of 1st FY (March 31, 2025)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.	N.A.

changes in Directors updated till May 30, 2025.

\*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

## 9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document:** Not Applicable
- (ii) **Actual implementation:** Not Applicable
- (iii) **Reasons for delay in implementation, if any:** Not Applicable.

## 10. Status of utilization of issue proceeds

- (i) **As disclosed in the offer document :**

The Company propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds, as set forth in the table below:

(in ₹ million)

Sr. No.	Particulars	Total estimated amount/ expenditure	Amount to be funded from the Net Proceeds	Estimated deployment of the Net Proceeds	
				Fiscal 2025	Fiscal 2026
1	Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	229.84	229.84	229.84	NA
2	Investment in certain Subsidiaries the repayment/prepayment, in full or in part, of certain outstanding borrowings	46.00	46.00	46.00	NA

3	Funding the capital expenditure requirements for purchase of new machinery for the Company	435.07	435.07	202.14	232.92
4	Investment in the Subsidiary, Bizdent Devices Private Limited, for the capital expenditure requirements for the purchase of new machinery	250.04	250.04	100.19	149.85
5	General Corporate Purpose	320.75	320.75	250.00	70.75
<b>Total</b>		<b>1281.70</b>	<b>1281.70</b>	<b>828.17</b>	<b>453.52</b>

**(ii) Actual utilization:**

Sr. No.	Item Head	Amt. as proposed in the offer document	Amount utilized			Total unutilized amt.	Comments of the Monitoring Agency
			As at the beginning of the quarter	During the quarter	At the end of the quarter		
1	Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	229.84	Nil	229.84	229.84	Nil	No Comments
2	Investment in certain Subsidiaries for the repayment/prepayment, in full or in or in part, of certain outstanding borrowings*	46.00	Nil	Nil	Nil	46.00	No Comments
3	Funding the capital expenditure requirements purchase of new machinery for the Company	435.07	Nil	7.43	7.43	427.64	Reimbursement taken for INR 3,89 Million incurred earlier by the company from its internal accruals
4	Investment in the Subsidiary, Bizdent Devices Private Limited, for capital expenditure requirements for the purchase of new machinery	250.04	Nil	Nil	Nil	250.04	No Comments
5	General Corporate Purpose	320.75	Nil	94.10	94.10	226.65	No Comments
<b>Total</b>		<b>1281.70</b>	<b>Nil</b>	<b>331.37</b>	<b>331.37</b>	<b>950.33</b>	

\* One month delay in utilisation of funds.

- (ii) **Reasons for deviation, if any:** No deviation - The utilization of the issuance proceeds is in line with the objects of the issue except as stated below –

Delay of one month in Investment in certain Subsidiaries for the repayment/prepayment, in full or in or in part, of certain outstanding borrowings.

Reason for delay- Limited time available to complete formalities for investment in subsidiary before year end.

The unutilized amount has been deployed in fixed deposit as follows :

Sr. No.	Type of instrument and name of the entity invested in	Amt. invested earning [Rs. million]	Return on Investment [%]
1	Fixed Deposit with ICICI Bank	30.00	4.75
2	Fixed Deposit with ICICI Bank	100.00	4.75
3	Fixed Deposit with ICICI Bank	100.00	4.75
4	Fixed Deposit with ICICI Bank	60.7	4.75
5	Fixed Deposit with ICICI Bank	30.00	4.75
6	Fixed Deposit with ICICI Bank	25.00	3.00
7	Fixed Deposit with ICICI Bank	100.00	4.75
8	Fixed Deposit with ICICI Bank	100.00	4.75
9	Fixed Deposit with ICICI Bank	30.10	5.75
10	Fixed Deposit with ICICI Bank	30.20	6.00
11	Fixed Deposit with ICICI Bank	30.30	6.50
12	Fixed Deposit with ICICI Bank	30.40	6.50
13	Fixed Deposit with ICICI Bank	30.50	6.85
14	Fixed Deposit with ICICI Bank	30.60	7.00
15	Fixed Deposit with ICICI Bank	30.70	7.00
16	Fixed Deposit with ICICI Bank	30.80	7.00
17	Fixed Deposit with ICICI Bank	30.90	7.30
18	Fixed Deposit with ICICI Bank	31.00	7.30
19	Fixed Deposit with ICICI Bank	31.10	7.30
20	Fixed Deposit with ICICI Bank	31.20	7.30
21	Fixed Deposit with ICICI Bank	37.30	7.30
	<b>Total Fixed Deposit</b>	<b>950.80<sup>^</sup></b>	
22	Balance lying in public offer account as 31 <sup>st</sup> March 2025	252.40 <sup>*</sup>	
	<b>Total</b>	<b>1203.20</b>	

<sup>^</sup>The amount of fixed deposit reinvested includes an accrued interest amount of INR 0.46 Million

<sup>\*</sup>The amount pertains to Unutilized issue expenses related to both the selling shareholders and the company's share. It also includes amounts that remain pending for reimbursement as of 31st March 2025.

Source: Monitoring Agency Report dated May,15, 2025 for the quarter ended March, 31, 2025.

#### 11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	No deviation - The utilization of the issuance proceeds is in line with the objects of the issue.
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	

(c) Any other reservations expressed by the monitoring agency about the end use of funds	
--	--

Source : Monitoring Agency Report dated May,15, 2025 for the quarter ended March, 31, 2025.

## 12. Pricing Data

**Issue Price (Rs.):** 428/-

**Designated Stock Exchange:** BSE Limited

**Listing Date:** January 20, 2025

Price parameters	At close of listing day (i.e. January 20, 2025)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day#	As at the end of 1st FY after the listing of the issue (May 31, 2025)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	550.65	350.8	406.70	444.05	583.70	312.95
BSE Sensex	77,073.44	75,967.39	78,553.20	77,414.92	85,978.25	70,234.43
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)*			As at the end of 3rd FY after the listing of the issue (March 31, 2027)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	NA	NA	NA	NA	NA	NA
BSE Sensex	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

\* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed # 90<sup>th</sup> day being Saturday (19<sup>th</sup> April 2025) & previous day before that was public holiday (18<sup>th</sup> April, 2025 Good Friday), henceforth data has been taken of earliest working day i.e. 17<sup>th</sup> April, 2025.

**13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting Ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2025) <sup>(3)</sup>	At the end of 2nd FY (March 31, 2026) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2027) <sup>(2)</sup>
EPS	<b>Issuer:</b>	--	--	--	--
	Consolidated (Basic)	4.80	6.07	N.A	N.A
	Consolidated (Diluted)	4.80	6.05	N.A	N.A
	Peer Group :	--	--	--	--
	Poly Medicure Limited	Basic – 26.92 Diluted – 26.90	Basic – 34.13 Diluted – 34.11	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	<b>Issuer:</b>	--	--	--	--
	Consolidated	83.76	73.15	N.A	N.A
	Peer Group	--	--	--	--
	Poly Medicure Limited	94.02	65.69	N.A	N.A
	Industry Composite:	94.02	N.A	N.A	N.A
RoNW (%)	<b>Issuer:</b>	--	--	--	--
	Consolidated	78.78	12.17	N.A	N.A
	Peer Group	--	--	--	--

	Poly Medicure Limited	19.05	12.24	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	<b>Issuer:</b>	--	--	--	--
	Consolidated	8.63	37.95	N.A	N.A
	Peer Group	--	--	--	--
	Poly Medicure Limited	153.22	272.96	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A

**Notes:**

- (1) Prospectus dated January 16, 2025.  
(2) Not disclosed as the reporting for the relevant fiscal years has not been completed.  
(3) Source :Audited Financial Results as on March 31, 2025.

**14. Any other material information**

Particulars	Date
The Company has informed about the change of name of Registrar and Share Transfer Agent from Link Intime India Private Limited to MUFG Intime India Private Limited with effect from 31st December, 2024.	29-January-2025
<p>The Company has informed about the board's approval for the following:</p> <ol style="list-style-type: none"> <li>1) To grant in- principal approval for providing an unsecured loan to Signature Smiles Dental Clinic Pvt. Ltd, a subsidiary of the Company up to Rs. 2,00,00,000/- (Rupees Two Crores Only) in one or more tranches.</li> <li>2) To grant in- principal approval in- principal approval for investment in Bizdent Devices Private Limited, a wholly owned Subsidiary of the Company up to Rs. 20,00,00,000/- (Twenty Crores Only) in one or more tranches.</li> </ol> <p>The Company further informed that company will update further at the time of execution of definitive agreements for the above-mentioned transactions.</p>	13-February-2025
<p>The Company has informed about the order received from the Honorable High Court of Bombay Commercial Suit No.243 of 2022 filed by the Company against Mr. Yogesh Bagul and others (hereinafter referred to as Defendant") .</p> <p>The Company further informed that pursuant to court order company has asked to hand over seized products,machinery and items to the Company lying at Unit No. 497/1 at Lohiya Compound, licensed premises of the Defendant at the cost of the company within a period of three weeks' time from the date of order.</p>	10-March-2025
<p>The Company has informed about the board approval at its Board meeting as follows :</p> <ol style="list-style-type: none"> <li>1) Appointment of M/s. M. Jawadwala &amp; Co., Practicing Company Secretaries, as the Secretarial Auditors of the Company to conduct secretarial audit for the FY 2024-25.</li> <li>2) Revision in the investment limits from up to ₹20 Crores to up to ₹55 Crores in one or more subsidiaries or associate company to meet the objects of IPO.</li> </ol>	21-March-2025

3) Approval for the investment limit up to ₹ 8.70 Crores (out of overall limit of up to ₹55 Crores) or more tranches in M/s Laxmi Dental Lab USA, Inc. foreign subsidiary of the Company.	
The Company has informed about the order received from the Hon'ble Special Judge of CBI, in CBI Vs Ashok Kumar Singh & Ors. related to discharge of Mr. Rajesh Khakhar (Accused No. 8), Promoter & Whole-time Director of the Company.	22-March-2025
The Company has informed about the change of its CIN U51507MH2004PLC147394 to L51507MH2004PLC147394 pursuant to the listing of its equity shares on the stock exchanges.	24-March-2025
The Company has informed about the loan agreement ("the Agreement") entered between Laxmi Dental Limited ("the Company/Lender") and Signature Smiles Dental Clinic Private Limited, a Subsidiary of the Company (hereinafter "the Borrower") to grant a loan for an aggregate amount not exceeding INR 75 Lakhs, in one or more tranches, subject to compliance with the applicable laws.	02-April-2025
The Company has informed about the acquisition of shares in "Laxmi Dental Lab USA INC." ("Foreign Material Subsidiary"), up to an amount of USD 10,00,000/- in pursuance to an Investment Agreement with Laxmi Dental Lab USA INC. dated December 24, 2024 (entered prior to the Company's listing), to formalize the terms of the strategic investment.  The Company further informed that they have obtained the necessary approval from the Reserve Bank of India ("RBI"), for transferring the amount of USD 10,00,000/- and the amount has been transferred on April 16, 2025, to acquire shares in its foreign material subsidiary, as per the Foreign Exchange Management (Overseas Investment) Regulations, 2022 and Foreign Exchange Management (Overseas Investment) Directions, 2022.	16-April-2025
The Company has informed about that pursuant to its corporate announcement dated 16 <sup>th</sup> April, 2025 regarding the acquisition of shares in "Laxmi Dental Lab USA INC." ("Foreign Material Subsidiary"), company has been allotted 10,000 equity shares of USD 100 each at par, fully paid up, against the payment of subscription money of USD 10,00,000/- (Rs.8.57 Crores) to Laxmi Dental Lab USA INC.  The Company further informed that pursuant to the aforesaid allotment resulting into increase of shareholding of the Company from 55.56% to 71.43% in Laxmi Dental Lab USA INC.	24-April-2025
The Company has informed about the acquisition of shares in Bizdent Devices Private Limited ("BDPL"), its wholly owned subsidiary and transfer of an aggregate amount not exceeding Rs. 40,91,46,972/- by way of subscription to a rights issue of up to 8,93,334 equity shares of BDPL, at an issue price of Rs. 458/- per equity share.	28-April-2025
The Company has informed about that pursuant to its corporate announcement dated 28 <sup>th</sup> April, 2025 regarding the acquisition of shares in "Bizdent Devices Private Limited." ("wholly owned Subsidiary"), company has been allotted 8,93,334 equity shares of Rs. 458/- each at par, fully paid up, against the payment of subscription money of Rs. 40,91,46,972 to Bizdent Devices Private Limited.	29-April-2025

Source- Stock Exchange Filings

All the above information has been updated till May 30, 2025, unless indicated otherwise.